Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01364779

Enrollment

Registered

2011-06-02

Start date

2010-04-30

Completion date

2012-03-31

Last updated

2013-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Keywords

aspirin, Chronic kidney disease

Brief summary

The primary objective of the study is to determine the prevalence of aspirin resistance in chronic kidney disease patients. The secondary objectives are to determine possible risk factors contributing to aspirin resistance in this population.

Detailed description

A cross-sectional of aspirin resistance in hemodialysis patients previously done in our institution showed that 23/66 (34.7%) hemodialysis patients were aspirin resistant. In a recent systematic review, renal impairment was associated with aspirin resistance . This association was seen in only two out of the twenty studies used in this meta-analysis . Both these studies are from the same center with a predominant Asian population. In this study we will try to evaluate the prevalence of aspirin resistance in CKD patient without being limited to a specific ethnicity.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with known structural kidney disease as evident by history or by urinalysis and CKD stage III or IV determined by MDRD formula and who are taking aspirin.

Exclusion criteria

* Younger than 18 years of age. * Bleeding disorder or myeloproliferative disorders. * Thrombocytopenia with platelets \< 100.000. * Malignancy. * Acute hemorrhagic disease. * A recent history of receipt of platelet glycoprotein IIb/IIIa blockers. * Liver disease as evident by abnormal liver function and total bilirubin \> 2mg/dl. * use of anticoagulation.

Design outcomes

Primary

Measure	Time frame	Description
prevalence of aspirin resistance in chronic kidney disease patients	2 years	Blood drawn for the Accumetric test

Secondary

Measure	Time frame	Description
risk factors contributing to aspirin resistance in this population.	2 years	risk factors

Countries

United States

Outcome results